Cognitive Effects of Citicoline in Men and Women With Age-Associated Memory Impairment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-02

Study Completion Date

2018-12-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this trial is to determine the effects of citicoline on cognitive performance in healthy Men and Women with Age-Associated Memory Impairment compared to a placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cognitive Effects of Citicoline on Attention in Healthy Mean and Women

NCT04967157

Healthy

COMPLETED NA

Improving Sleep and AD Biomarkers

NCT06029894

Mild Cognitive Impairment Alzheimer Disease

ACTIVE_NOT_RECRUITING NA

Improving Sleep and Cognition in Alzheimer's Disease

NCT05200208

Alzheimer Disease

COMPLETED NA

Cognizin Citicoline Dosing in a Healthy Adolescent Male Population

NCT01582113

Neurocognitive Improvement

COMPLETED EARLY_PHASE1

Study to Assess the Efficacy of Cognitex

NCT00719953

Elderly Memory Impairment

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a 12-week, randomized, double-blind, placebo-controlled trial of citicoline in healthy men and women with Age-Associated Memory Impairment. Cognitive assessments will be performed to determine whether citicoline administration with supportive memory, compared to placebo administration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo supplement

Intervention Type DIETARY_SUPPLEMENT

Cellulose

Cognizin

Group Type EXPERIMENTAL

Citicoline supplement

Intervention Type DIETARY_SUPPLEMENT

Cognizin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo supplement

Cellulose

Intervention Type DIETARY_SUPPLEMENT

Citicoline supplement

Cognizin

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Placebo Cognizin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male or female, 50-85 years of age
* at least a high school diploma or the equivalent
* self-reported memory loss
* scores ≥24 on the Mini-Mental State Examination, ≥85 on the Kaufman Brief Intelligence Test, Second Edition, ≤5 on the Geriatric Depression Scale, and 4, 3, or 2 on the Spatial Span Test
* no health conditions that would prevent him or her from fulfilling the study requirements on the basis of medical history and routine laboratory test results

Exclusion Criteria

* color blind
* abnormal laboratory test results
* major medical or neurological illness
* female who is pregnant, planning to be pregnant during the study period
* requiring treatment with a drug which might obscure the action of the study treatment

Minimum Eligible Age

50 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes